Compare Eli Lilly And Co (LLY) vs MINISO Group Holding Ltd (MNSO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs MINISO Group Holding Ltd — how do they compare? Eli Lilly And Co trades at $1,218.49 (market cap $1.08T), while MINISO Group Holding Ltd trades at $11.87 (market cap $3.62B). The key difference: Eli Lilly And Co is far larger — about 298.3× MINISO Group Holding Ltd's market cap, and MINISO Group Holding Ltd pays the higher dividend (5.53%). Which is the better fit depends on your goals.
| LLY | MNSO | |
|---|---|---|
Market Cap | $1.08T | $3.62B |
Sector | Health | Technology |
52-Week High | $1.24K | $26.63 |
52-Week Low | $639.43 | $11.30 |
Enterprise Value | $1.13T | $4.29B |
Dividend Yield | 0.57% | 5.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,231.58, up 3.87% in the past 24 hours, reflecting strong momentum near its 52-week high. The stock exhibits bullish technical signals with robust fundamentals, including 48% revenue growth in Q2 2026 and a net income margin of 33.53%. Recent news highlights legal actions against black-market drug sales and positive analyst sentiment following earnings beats.
Outlook remains positive with a consensus price target of $1,380, though high valuation ratios (P/E 40.79) and regulatory risks pose challenges. Earnings growth and pipeline advancements, like retatrutide, drive upside potential, but investors should monitor competitive pressures and execution risks.
MNSO trades at $11.9, down 4.95% in the last session, with a neutral technical signal and bearish moving averages. Recent earnings showed a Q1 2026 beat but prior misses, while fundamentals include a P/E of 12.16 and net margin of 8.98%. The company announced a $2 billion share repurchase in June 2026, supporting sentiment amid mixed performance.
Outlook is cautiously optimistic with 75% analyst buy ratings, but risks include margin pressure from SG&A costs and competitive retail markets. The stock offers value if earnings growth sustains, though volatility from recent declines warrants monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About MINISO Group Holding Ltd
MINISO Group Holding Ltd is a global lifestyle product retailer known for its aesthetically pleasing, high-quality, and low-cost goods. The company operates a network of branded stores worldwide, offering a diverse range of merchandise, including household goods, cosmetics, toys, and digital accessories. MINISO's business model emphasizes rapid product iteration, efficient supply chain management, and a joint venture and franchise partner network to facilitate its global expansion.
Read more on MNSO →
